Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Plan B OTC Submission Fails On Lack Of Data In Teens

This article was originally published in The Tan Sheet

Executive Summary

Barr Labs will continue to work with FDA toward approval of emergency contraceptive Plan B (levonorgestrel .75 mg) for OTC use, the company said in a May 6 statement

Related Content

FDA Topsiders Must Testify In Plan B Case – Judge
Emergency Contraception OTC Sale Backed By BMJ Study Authors
No Plan B Switch Parade As User Fee Deadline Comes And Goes
OTC Emergency Contraception Does Not Increase Sexual Activity – Study
AMA Urges Plan B Decision Reversal, Resolves To Increase EC Access
Advisory Panel Members Respond To Wood Editorial In NEJM On Plan B
Pediatric Medical Groups Oppose Age Restrictions On OTC Plan B
Dual Status Rx/OTC Plan B In The Works? Barr Weighs Its Options
Plan B Decision Mobilizes House Members To Seek FDA Integrity Review
One-dose “morning after” pill?





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts